Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
COX6C
REST API REST API
Homo sapiens
COX6C is differentially expressed in 244 experiments: 99 organism parts: bone marrow, liver, ... (97 more);, 146 disease states: normal, acute promyelocytic leukemia, ... (144 more);, 71 cell types 346 cell lines 30 compound treatments and 75 other conditions.
Orthologs COX6C (Danio rerio)   COX6C (Gallus gallus)   Cox6c (Mus musculus)   COX6C_BOVIN (Bos taurus)   LOC100365890 (Rattus norvegicus)   Cox6c (Rattus norvegicus)   cox6c (Xenopus laevis)   XM_850997.1 (Canis familiaris)   ENSCAFG00000007660 (Canis familiaris)   ENSCAFG00000011223 (Canis familiaris)   ENSCAFG00000006734 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term mitochondrial inner membrane, generation of precursor metabolites and energy, membrane, respiratory electron transport chain, integral to membrane, cytochrome-c oxidase activity, mitochondrion
InterPro Term Cyt_c_oxidase_su6c
UniProt Accession P09669
Search EB-eye ENSG00000164919
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
HCC1954
2
E-MTAB-37, E-GEOD-29119
HCC38
2
E-MTAB-62, E-MTAB-37
HepG2
2
E-GEOD-21154, E-MTAB-37
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
340 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13987, E-GEOD-11755, ... (36 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-8286, E-GEOD-3982
bronchial epithelial
1
E-AFMX-5
CXCR5(lo)ICOS(int) CD4 T cell
1
E-MEXP-750
T-ALL
1
E-GEOD-19069
breast cancer
1
E-GEOD-29119
CD71+ early erythroid
1
1
E-AFMX-5
65 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-MEXP-2280, E-GEOD-16363, ... (49 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-96, E-GEOD-995
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
Burkitt's lymphoma
1
2
E-MTAB-37, E-GEOD-96
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
glioblastoma
2
E-MTAB-37, E-GEOD-6014
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
140 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (20 experiments)

Factor Value U/D Experiments
chloroguine
1
E-GEOD-5418
lipopolysaccharide
1
E-TABM-868
bacterial endotoxin
1
E-GEOD-3284
N-nitrosodimethylamine
1
E-GEOD-6907
glutamine
1
E-MEXP-1335
Cxcl12
1
E-GEOD-7307
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-GEOD-4667, ... (6 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-2466, E-MEXP-421, E-GEOD-22593, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-11886

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.409 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM